Testing duvakitug for active Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old (or 16 to 18 if fully developed).
- You have had moderately to severely active Crohn's disease for at least 3 months.
- You have tried other treatments (like conventional therapies or advanced therapies) and they didn't work well enough, stopped working, or caused side effects.
- You are not currently taking certain medications without stable doses, and you have not been treated with another drug like duvakitug before.
- You do not have ulcerative colitis, indeterminate colitis, or missing large sections of your bowel.
- You do not have high-grade dysplasia (abnormal cells) in your digestive tract.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called brivekimig for people with moderate-to-severe Crohn's disease. It aims to see if the drug can reduce symptoms and inflammation better than standard treatments.
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.